Journal
NATURE REVIEWS CANCER
Volume 10, Issue 2, Pages 130-137Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2787
Keywords
-
Categories
Funding
- US National Institutes of Health [DK083531, EB001987]
Ask authors/readers for more resources
Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit multiple kinases, how do we choose which ones? In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available